source
- STAT+: Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicatedIn this edition of AI Prognosis: A conversation about benchmarking leading clinical chatbots, investor view on AI in biopharma, and more.STAT · 9h ago↗ source
- ‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrenceA standard chemotherapy drug loaded in nanoparticles has been able to penetrate the blood-brain barrier when administered shortly after resection of the tumor, new research has suggested.Fierce Biotech · 11h ago↗ source
- ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a whileBiogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.